Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IBN's Droplet Array Sheds Light on Drug-Resistant Cancer Stem Cells

Published: Wednesday, May 09, 2012
Last Updated: Wednesday, May 09, 2012
Bookmark and Share
Cheaper, faster and convenient drug screening using limited samples.

Researchers at the Institute of Bioengineering and Nanotechnology (IBN) have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs).

Published recently in Nano, this new technology could boost the development of more effective cancer drugs.

In a tumor, CSCs form a small and distinct class of cancer cells that are more resistant to chemotherapy. Similar to stem cells found in human tissues, CSCs can produce and differentiate into different cell types. If CSCs are not eradicated, they can repopulate the tumor and lead to cancer recurrence.

Hence, it is important for researchers to understand the efficacy of anti-cancer drugs against CSCs.

However, since CSCs are so scarce - they make up approximately 1% of cancer cells - their study has been hampered by conventional drug screening methods, which require large sample volumes and are slow and expensive.

A team of researchers led by IBN Executive Director, Professor Jackie Y. Ying, has developed a miniaturized biological assay called the Droplet Array to perform cheaper, faster and more convenient drug screening using limited samples.

In traditional biological assays, microplates - a flat plate with multiple wells in which samples are placed - are commonly used, and each well requires at least 2,500 or 5,000 cells, to be present for viable analysis.

By comparison, IBN's Droplet Array is a flat, rectangular glass plate on which a series of spots, each 2 millimeters in diameter, are arranged. The samples are pipetted into these tiny spots, making them appear like droplets.

The plate is then coated with a layer of proprietary oil to prevent evaporation and cross contamination between the sample droplets during the rinsing process.

An accompanying bench-top device to automate the rinsing process of the plate has also been developed.

Being one-fifth the size of a well in a standard microplate, each spot on IBN's Droplet Array requires only 500 cells for screening.

This massive reduction in sample volume not only saves money, but is also particularly advantageous for studying scarce quantities of target cells, such as CSCs.

Using the Droplet Array, the IBN researchers investigated the drug responses of CSCs extracted from breast, liver and colon cancer cells. It was found that chemotherapeutic drugs such as doxorubicin, which usually induce cell death in liver cancer cells, demonstrated poor efficacy in liver CSCs.

The CSCs from the breast and colon tumors also showed much greater ability to survive the effects of anti-cancer drugs.

Animal studies were conducted to validate the findings of the Droplet Array. CSCs and non-CSCs from liver tumors were implanted into two different sets of mice at the same time.

After 6 weeks, tumors were formed in the mice implanted with CSCs, whereas the mice without CSCs did not develop any tumors.

Tumors extracted from the mice with CSCs also showed blood vessel formation, which confirmed the self-renewal property of these cells.

The drug resistance properties of CSCs have been widely discussed in recent years but until now, it has been challenging to quantify this correlation.

Using the Droplet Array, IBN researchers have successfully demonstrated that CSCs can survive chemotherapy and drive metastasis.

Professor Jackie Y. Ying said, "The Droplet Array marks a significant breakthrough in nanotechnology and lab-on-a-chip concepts, and provides an efficient platform for accelerating drug screening and development. The study of cancer stem cells, in particular, is an exciting application of this technology for both the academic and pharmaceutical industries. We hope that this finding will facilitate the development of more effective cancer drugs. We also hope to leverage on the Droplet Array's capabilities to complement/replace animal models for drug toxicity testing, and develop new cancer diagnostics."

Designed for ease of use, this miniaturized biochip is compatible with existing laboratory instruments, such as plate readers and microscopes, and reduces the set-up cost and the need to purchase additional equipment when adapting to this new technology.

The Droplet Array technology is currently being commercialized by IBN's first spinoff company, Curiox Biosystems Pte Ltd, as DropArray™.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Paving the way to Better Ovarian Cancer Diagnosis
Aïcha BenTaieb will present her invention for automated identification of ovarian cancer’s many subtypes at an international conference this fall.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Futuristic Brain Probe Allows for Wireless Control of Neurons
NIH-funded scientists developed an ultra-thin, minimally invasive device for controlling brain cells with drugs and light.
Microfluidic Device Mixes And Matches DNA For Synthetic Biology
Researchers have developed a microfluidic device that quickly builds packages of DNA and delivers them into bacteria or yeast for further testing.
Artificial Pancreas Controls Diabetes
Scientists are reporting the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar, or glucose, level and can automatically release insulin as needed.
Major Step for Implantable Drug-Delivery Device
MIT spinout signs deal to commercialize microchips that release therapeutics inside the body.
Smart Insulin Patch Could Replace Painful Injections for Diabetes
A joint effort between diabetes doctors and biomedical engineers could revolutionize how people with diabetes keep their blood sugar levels in check.
The Secrets of Secretion
Researchers have hacked nature's blueprints to create a new technology that could have broad-reaching impact on drug delivery systems and self-healing and anti-fouling materials.
New Tool on Horizon for Surgeons Treating Cancer Patients
Surgeons could know while their patients are still on the operating table if a tissue is cancerous, according to researchers.
Heartbeat on a Chip Could Improve Pharmaceutical Tests
A gravity-powered chip that can mimic a human heartbeat outside the body could advance pharmaceutical testing and open new possibilities in cell culture because it can mimic fundamental physical rhythms.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!